Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, T-Cell 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melanoma × Tetrahydrouridine × Clear all
NCT02839694 2018-07-05

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡